The changing pattern of Candida infections;HET VERANDEREND PATROON VAN CANDIDA-INFECTIES

Nederlands Tijdschrift voor Geneeskunde

Volumn 140, Issue 3, 1996, Pages 148-151

  Kullberg, B J ^a,b   Voss, A ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Afd Alacmeen Interne Geneeskunde ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE;

ARTICLE; CANDIDIASIS; HOSPITAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; DRUG RESISTANCE; HUMANS; OPPORTUNISTIC INFECTIONS;

EID: 0030030776     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Beck-Sagué CM, Jarvis WR Secular trends in the epidemiology of nosocomial fungal infections in the United States. 1980-1990. J Infect Dis 1993;167:1247-51.
2. Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infection. Am J Med 1991;91 Suppl 3B: 72S-5S.
3. Wey SB, Mori M, Pfaller MA, Woolson RF. Wenal RP Hospitalacquired candidemia. The attributable mortality and excess length of stay. Arch intern Med 1988;148 2642-5.
4. Kullberg BJ, Wout JW van 't. Behandeling en profylaxe van gegeneraliseerde mycosen. Ned Tijdschr Geneeskd 1995;139:1436-41.
5. Wout JW van 't, kullberg BJ, Meis JFGM, Reiss P. Schimmelinfecties bij patiënten met een gestoorde afweer. Ned Tijdschr Geneeskd 1995-139;1430-6.
6. Guiot HFL, Fibbe WE, Wout JW van 't, Risk factors for fungal infection in patients with malignant hematologic disorders. implications for empirical therapy and prophylaxis. Clin Infect Dis 1994;18:525-32.
7. Bow EJ, Loewen R, Cheang MS, Schacter B, Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen. Clin Infect Dis 1995;21:361-9.
8. Walsh TJ, Pizzo PA. Experimental gastrointestinal and disseminated candidiasis in immunocompromised animals. Eur J Epidemiol 1992;8:477-83.
9. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med 1989;149:2349-53.
10. Wenzel R. Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 1995;20:1531-4.
11. Reagan DR. Pfaller MA, Hollis RJ, Wenzel RP. Characterization of the sequence of colonization and nosocomial candidemia using DNA fingerprinting and a DNA probe. J Clin Microbiol 1990;28:2733-8.
12. Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995,20:1526-30.
13. Voss A, Pfaller MA, Hollis RJ, Rhine-Chalberg J, Doebbeling BN. Investigation of Candida albicans transmission in a surgical intensive care unit cluster by using genomic DNA typing methods. J Clin Microbiol 1995;33:576-80.
14. Komshian SV, Uwaydah AK, Sobel JD, Crane LR. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis 1989;11.379-90.
15. Glauser MP, Eggimann P, Francioli P. Bille J. Schneider R, Chapuis G, et al. Efficacy of fluconazole in the prevention of surgical fungal infections Trends in invasive fungal infections 3. Brussels: Imedex. 1995;13.
16. Lecciones JA, Lee JW, Navarro EE, Witebsky FG, Marshall D, Steinberg SM, et al. Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes. Clin Infect Dis 1992; 14-875-83
17. Meunier F, Aoun M, Bitar N. Candidemia in immunocompromised patients. Clin Infect Dis 1992:14 Suppl 1:8120-S5.
18. Beutler SM, Young LS, Lindquist LA. Montgomerie JZ, Edwards JE jr. Delayed complications of candidemia. Program and abstracts of the 22nd lnterscience Conference on antimicrobial agents and chemotherapy Miami Beach. Fla.: American Society for Microbiology. 1982:154.
19. Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin infect Dis 1995;20:115-25.
20. Wingard JR, Dick JD, Merz WG, Sandford GR, Saral R, Burns WH. Pathogenicity of Candida tropicalis and Candida albicans after gastrointestinal inoculation in mice. Infect Immun 1980;29:808-13.
21. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusel infection among patients with bone mar-row transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991;325:1274-7.
22. Dupont B, Drouhet E, Fluconazole in the management of orophar-yngeal candidosis in a predominantly HIV antibody-positive group of patients. J Med Vet Myeol 1988;26:67-71.
23. Millon L, Manteaux A, Reboux G, Drobacheff C, Monod M, Barale T, et al. Fluconazole-resistant recurrent oral candidiasis in human immunodeficiency virus-positive patients: persistence of Candida albicans strains with the same genotype. J Clin Microbiol 1994; 32:1115-8.
24. Kitchen VS, Savage M, Harris JRW. Candida albicans resistance in AIDS [letter]. J Infect 1991;22:204-5.
25. Boken DJ, Swindells S, Rinaldi MG. Fluconazole-resistant Candida albicans. Clin Infect Dis 1993;17:1018-21.